China's Health Program to Support Financial Burden on Patients
-
Loading... - Bagus Setiawan
- 13 Dec 2024
- 57 Views
- 0 Like
- 0 Comment
China’s latest round of its bulk drug procurement program aims to ease the financial burden on patients by offering critical medications at significantly lower prices. The initiative, led by the National Healthcare Security Administration (NHSA), targets a broad range of health conditions and demonstrates the government’s commitment to making healthcare more accessible and affordable for its citizens.
The bulk buy program allows drug manufacturers to offer lower prices for generic medications in exchange for large-volume contracts with public hospitals. This approach not only helps to lower the cost of essential medicines but also ensures that patients have access to necessary treatments without incurring excessive expenses.
The latest bidding for this program took place in Shanghai, with preliminary results indicating that 62 types of medicines have successfully won bids. These medications span various medical fields, including:
- High blood pressure
- Diabetes
- Cancer
- Cardiovascular diseases
- Infectious illnesses
- Mental health
Among the selected medications is a specialized doxorubicin injection, which is used in the treatment of breast cancer. This particular formulation has been noted for causing fewer side effects compared to standard doxorubicin products, highlighting the program's focus on improving patient outcomes.
Since the inception of the centralized procurement program in 2018, China has conducted ten rounds of bidding, covering a total of 435 types of medicines. The initiative has had a substantial impact on the healthcare system, with estimates suggesting that it has saved the nation's medical insurance funds nearly 500 billion yuan (approximately $68.6 billion).
This program is part of China's broader strategy to enhance healthcare affordability and accessibility for its population. By negotiating lower prices for essential medications, the government aims to ensure that patients can receive the treatments they need without facing overwhelming financial strain.
China's latest round of the bulk buy program represents a continued commitment to reducing healthcare costs and improving access to essential medications for patients. As the country navigates the complexities of its healthcare system, initiatives like this play a crucial role in supporting the financial well-being of its citizens while promoting better health outcomes across the population.
